US4623620A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Enucleated granulocytes, their preparation and use
Assignee: Stichting Vrienden Van de Stichting Dr Karl Landsteiner
•
Filing: 1983-08-02
•
Granted: 1986-11-18
•
Expires: 2003-08-02
Abstract
Abstract Granulocytes, particularly neutrophilic granulocytes, also called polymorphonuclear leukocytes (PMN), have been found to retain their immunological properties after enucleation. Moreover, in contrast with normal granulocytes, enucleated granulocytes are stable when stored in frozen condition. The invention relates to the enucleated granulocytes, especially in frozen condition, to a process for preparing the enucleated granulocytes, to a process for assaying antibodies against granulocytes, and to a kit for carrying out the latter process.
Inventors
- 👤 Dirk Roos
- 👤 Alwin A. Voetman
- 👤 Louis J. Meerhof
- 👤 Bertram Lubin
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 02:48
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/531; G01N33/5005; G01N33/569; G01N33/56966; G01N33/56972; Y; Y10; Y10S; Y10S435/00; Y10S435/81; Y10S435/966; Y10S435/975
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
41 words
A process for assaying antibodies against granulocytes in a sample, which comprises incubating the sample with enucleated granulocytes, and assaying the incubated sample to detect the formation of the product formed by the reaction of enucleated granulocytes and antibodies against granulocytes.
Claim 2
Dependent Claim
41 words
A process for assaying antibodies against granulocytes in a sample, which comprises incubating the sample with enucleated granulocytes, and assaying the incubated sample to detect the formation of the product formed by the reaction of enucleated granulocytes and antibodies against granulocytes.
Claim 3
Dependent Claim
20 words
The process of claim 1, which further comprises assaying the incubated sample to assay the amount of reaction product formed.
Claim 4
Dependent Claim
47 words
The process of claim 1 or 2, which comprises incubating a blood sample to be assayed with enucleated polymorphonuclear leukocytes, washing said incubated sample, incubating the washed sample with fluorescein isothiocyanate labeled antiglobulin serum, washing said labeled sample and reading the fluorescence of the reaction product formed.
Claim 5
Dependent Claim
49 words
The process of claim 1 or 2 in which the product formed by the reaction of enucleated granulocytes and antibodies against granulocytes is assayed by a means selected from the group consisting of observation of cell agglutination, complement binding reactions, labeled antibodies and subsequent reaction with cytotoxic effector cells.
Claim 6
Dependent Claim
19 words
The process of claim 4, in which the means are an immunofluorescence assay, an enzyme-immunoassay and a radio immunoassay.
Claim 7
Dependent Claim
26 words
A process of claim 3, in which the fluorescein isothiocyanate labeled antiglobulin serum is fluorescein isothiocyanate labeled F(ab') 2 fragments of sheep IgG against human globulin.
Claim 8
Dependent Claim
31 words
A kit having component parts capable of being combined for assaying antibodies against granulocytes, the kit comprising enucleated granulocytes typed for granulocyte-specific antigens, in a suspended medium, in a frozen condition.
Claim 9
Dependent Claim
31 words
A kit having component parts capable of being combined for assaying antibodies against granulocytes, the kit comprising enucleated granulocytes typed for granulocyte-specific antigens, in a suspended medium, in a frozen condition.
Claim 10
Dependent Claim
13 words
The kit of claim 7 additionally comprising one or more labeled antiglobulin sera.
Claim 11
Dependent Claim
23 words
The kit of claim 8, in which the antiglobulin sera is fluorescein isothiocyanate labeled F(ab') 2 fragments of sheep IgG against human globulin.
Claim 12
Dependent Claim
36 words
The kit of claim 7, additionally comprising (a) phosphate buffered saline pH 7.4 (b) bovine serum albumin (60 g/l) (c) human AB serum (d) aqueous glycerol solution 21% (wt/vol) and (e) aqueous paraformaldehyde solution 1% (wt/vol).
Claim 13
Dependent Claim
14 words
The kit of claim 10, in which the enucleated granulocytes are enucleated polymorphonuclear leukocytes.
Claim 14
Dependent Claim
32 words
The kit of claim 11 in which the suspending medium for the enucleated polymorphonuclear leukocytes is phosphate buffered saline, pH 7.4, containing 10% (vol/vol) fetal calf serum and 10% (vol/vol) dimethyl sulfoxide.
References Cited (Backward Citations)
US4111199A
Cited
GB2013211A
Cited
US4235869A
Cited
US4328183A
Cited
US4251995A
Cited
US4327799A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-11-17 | 1990-05-19 | 1990-11-18 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-11-17 | 1994-05-19 | 1994-11-18 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-11-17 | 1998-05-19 | 1998-11-18 | $7700.00 | Window Closed / Lapsed |